# Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide

> **NCT03566511** · PHASE2 · TERMINATED · sponsor: **Meredith Hawkins** · enrollment: 37 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Glucose, High Blood
- Glucose Metabolism Disorders (Including Diabetes Mellitus)

## Interventions

- **DRUG:** Diazoxide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03566511
- **Lead sponsor:** Meredith Hawkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-12
- **Primary completion:** 2020-08-01
- **Final completion:** 2020-08-01
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** Grant funding ended. NIDDK grant renewed without an MR aim. No plans to do future studies.
- **Last updated:** 2025-05-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03566511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03566511, "Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03566511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*